<DOC>
<DOCNO>EP-0630372</DOCNO> 
<TEXT>
<INVENTION-TITLE>
HETEROALKOXY BENZAZEPINES.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3155	A61K3155	A61P900	A61P900	A61P912	A61P1300	A61P1302	A61P1500	A61P1500	A61P2500	A61P2502	C07D40100	C07D40112	C07D40300	C07D40304	C07D40306	C07D40312	C07D40500	C07D40512	C07D40900	C07D40912	C07D41300	C07D41312	C07D41700	C07D41704	C07D41706	C07D41712	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61P9	A61P9	A61P9	A61P13	A61P13	A61P15	A61P15	A61P25	A61P25	C07D401	C07D401	C07D403	C07D403	C07D403	C07D403	C07D405	C07D405	C07D409	C07D409	C07D413	C07D413	C07D417	C07D417	C07D417	C07D417	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Alpha-adrenergic receptor antagonists having formula (I) which are useful to produce  alpha -adrenoceptor antagonism, pharmaceutical compositions including these antagonists, and methods of using these antagonists to produce  alpha -adrenoceptor antagonism in mammals.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SMITHKLINE BEECHAM CORP
</APPLICANT-NAME>
<APPLICANT-NAME>
SMITHKLINE BEECHAM CORPORATION
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DEMARINIS ROBERT MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
PFEIFFER FRANCIS RICHARD
</INVENTOR-NAME>
<INVENTOR-NAME>
DEMARINIS, ROBERT, MICHAEL
</INVENTOR-NAME>
<INVENTOR-NAME>
PFEIFFER, FRANCIS, RICHARD
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 HETEROALKOXY BENZAZEPINESFTF.T.D OF THE TNVFNTTONThis invention relates to novel substituted 2,3,4,5- tetrahydro-lH-3-benzazepine compounds having α-adrenergic receptor antagonist activity.RACy^ROTTND OF THF T FNTTONThe autonomic nervous system is separated into the cholinergic and adrenergic nervous systems. Norepinephrine, the neurotransmitter of the adrenergic nervous system, exerts its activity by interaction with receptors, (adrenoceptors) on the effector organs or on the nerve endings. The adrenoceptors are of two primary types: α and β. Based upon selectivity of the receptors for a series of agonists and antagonists, the a adrenoceptors have been subdivided into α^ and ct2 subtypes.A large amount of experimental evidence now supports the view that the (2 subtype is a heterogeneous adrenoceptor class. (For a general review see Timmermans and Van Zwieten, J. Med. Chf»τn-r 25., 1389 (1982)).Experiments using 6-chloro-9-(3-methyl-2-butenyloxy)-3- methyl-2,3,4,5-tetrahydro-lH-3-benzazepine (SK&F 104078) demonstrated that the classical adrenoceptors are heterogeneous and can be divided into SK&F 104078- insensitive and SK&F 104078-sensitive CI2 adrenoceptors. The latter variously are referred to as postjunctional CC2 adrenoceptors or, preferably, (X3 adrenoceptors. United States Patent No. 4,683,229, July 28, 1987. 

 As one of the primary regulators of peripheral vascular tone, α adrenoceptors long have been the targets of efforts to develop agents effective in changing vascular tone for use in treating diseases, such as hypertension, in which alterations in vascular resistance produce therapeutic benefits. Antihypertensive compounds presently in clinical use that function via interaction with a adrenoceptors include methyldopa, clonidine, and prazosin. Efforts to modulate sympathetic tone through interactions with a adrenoceptors have resulted in several compounds that interact somewhat selectively with α^ or 0C2 adrenoreceptors. Selective agonists include phenylephrine and methoxamine which preferentially activate α^ receptors; and clonidine, α-methyl-norepinephrine, and tramazoline which preferentially activate C-2 adrenoceptors. Examples of selective α-adrenoceptor antagonists include prazosin which has high selectivity for α^ adrenoceptors; and the C-2-selective blockers yohimbine and rauwolscine.United States Patent No. 4,469,634, dated September 4, 1984, describes allyloxy- and allythio- 2,3,4,5-tetrahydro- lH-3-benzazepines useful as intermediates for preparing <2 adrenoceptor affinity resins
</DESCRIPTION>
<CLAIMS>
 What is claimed is:
1. A compound having the formula:
in which:
X is H, Cl, Br, F, I, CF3, Cι_galkyl, COR
1
, C02R
2
, CONR
2
R
2
, CN, NO2, NR
3
R
4
, OR
3
, SR
1
, SCF3, or any accessible combination thereof up to three substituents; R is H, Cι_galkyl, or C3_5alkenyl; A is -0C0(CH2)1- - -0CH
2
CH=CH-, -C0
2
(CH
2
)1-4-,
~
(
CH2)o-6~' 
or
 ~
(CH
2
)
n
z(CH
2
)
m~' wherein n is 0-4 and m is 1-5, with the proviso that m and n taken together are no greater than 5;
Z is 0 or S; each R
1
 independently is Ci-galkyl or
(
CH
2
)
o-6P
hen
y
1
; each R
2
 independently is H, C _galkyl, or
(
CH
2
)
o-δPheny
1
'
R
3
 is H, Cx-galkyl, CHO, COR
1
, or SO2R
1
; R
4
 is H or Cx-galkyl; and
Het is a heteroaryl group selected from thienyl, furanyl, pyrazolyl, imidazolyl, pyrrolyl, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridazolyl, pyri idinyl, pyrazolyl, thiazolyl, pyridinyl, or tetrazolyl which are unsubstituted or substituted by Ci-galkyl, Ci-galkoxy, Cl, Br, F, I, NR
3
R
4
, C0 R
2
, CONR
2
R
2
, CN, or NO2; or a pharmaceutically acceptable salt thereof, provided that when X is H, Cl, Br, F, CF3, CH3, OCH3, OH, or OC(0)Cι-_.galkyl, A-Het is not -S(CH2)o-l"thienyl or -furanyl.
2. A compound of claim 1 having the formula: 


 in which:
X is H, Cl, Br, F, I, CF3, Cι_galkyl, COR
1
, C02R
2
, CONR
2
R
2
, CN, NO2, NR
3
R
4
, OR
3
, SR
1
, or SCF3, R is H, Cχ-_.galkyl, or C3_5alkenyl; A is -OCO.CH2)1-4-, -OCH
2
CH=CH-, -C0
2
 (CH
2
) 1-4-,
-
(
CH2)o-6~' 
or
 ~
(CH
2
)
n
z (CH
2
)
m~' wherein n is 0-4 and m is 1-5, with the proviso that m and n taken together are no greater than 5;
Z is 0 or S; each R
1
 independently is Ci-galkyl or
(
CH
2
)
o-6P
hen
y
1
' each R
2
 independently is H, C _galkyl, or 
(
CH
2
)
o-6P
hen
y
1
'"
R
3
 is H, Cι_galkyl, CHO, COR
1
, or SO2R
1
; R
4
 is H or C^-galkyl; and
Het is a heteroaryl group selected from thienyl, furanyl, pyrazolyl, imidazolyl, pyrrolyl, triazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridazolyl, pyrimidinyl, pyrazolyl, thiazolyl, pyridinyl, or tetrazolyl which are unsubstituted or substituted by C^-galkyl, C^-galkoxy, Cl, Br, F, I, NR
3
R
4
, C0
2
R
2
, C0NR
2
R
2
, CN, or NO2; or a pharmaceutically acceptable salt thereof, provided that when X is H, Cl, Br, F, CF3, CH3, OCH3, OH, or OC(0)Cι_galkyl, A-Het is not -S(CH2) o-i
_
thienyl or -furanyl.
3. A compound of claim 2 wherein X is Cl, Br, F, or I. 


 4. A compound of claim 3 wherein Het is pyrazolyl, furanyl, thienyl, triazolyl, pyridinyl, or pyrrolyl with each heteroaryl group being unsubstituted or substituted by Cl or CH3.
5. A compound of claim 4 wherein R is CH3.
6. A compound of claim 5 which is 6-chloro-9-(3- furanylmethoxy)-2,3,4,5-tetrahydro-3-methyl-lH-3- benzazepine or a pharmaceutically acceptable salt thereof.
7. A compound of claim 5 which is: 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(lH-pyrazol- 1-ylmethoxy)-lH-3-benzazepine;
6-chloro-9-(4-chloro-lH-pyrazol-l-ylmethoxy)-2,3,4,5- tetrahydro-3-methyl-lH-3-benzazepine;
6-chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3- methyl-lH-3-benzazepine; 6-chloro-9-[3-(2-furanyl)-2-propenyloxy]-2,3,4,5- tetrahydro-3-methyl-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2-thienyl- ethoxy)-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(3-thienyl- methoxy)-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H- pyrazol-1-yl)ethoxy]-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4- triazol-l-ylmethoxy)-lH-3-benzazepine; 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4- pyridinylmethoxy)-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-1,2, - triazol-1-yl)ethoxy]-lH-3-benzazepine;
6-chloro-9-[ (4-chloro-lH-pyrazol-l-ylmethoxy)- methyl]-2,3,4,5-tetrahydro-3-methyl-lH-3-benzazepine; 6-chloro-9-[ (4-chloro-lH-pyrazol-l-ylmethoxy)- carbonyl]
-2,3,4,5-tetrahydro-3-methyl-lH-3-benzazepine; 


 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(lH-pyrrol-1- yl)-lH-3-benzazepine;
6-chloro-9-(2,5-dimethyl-lH-pyrrol-l-yl)-2,3,4,5- tetrahydro-3-methyl-lH-3-benzazepine; 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(lH-pyrrol-1- ylmethyl)-lH-3-benzazepine;
6-chloro-9-[3-(4-chloro-lH-pyrazol-l-yl)propyl]- 2,3,4,5-tetrahydro-3-methyl-lH-3-benzazepine; or
6-chloro-9-[5-(4-chloro-lH-pyrazol-l-yl)pentyl]- 2,3,4,5-tetrahydro-3-methyl-lH-3-benzazepine; or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a compound of claim 1 and a suitable pharmaceutical carrier.
9. A pharmaceutical composition of claim 8 wherein the compound is 6-chloro-9-(3-furanylmethoxy)-2,3,4,5- tetrahydro-3-methyl-lH-3-benzazepine.
10. A pharmaceutical composition of claim 8 wherein the compound is:
6-chloro-9-(4-chloro-lH-pyrazol-l-ylmethoxy)- 2,3, ,5-tetrahydro-3-methyl-lH-3-benzazepine; 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(lH-pyrazol- 1-ylmethoxy)-lH-3-benzazepine;
6-chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3- methyl-lH-3-benzazepine;
6-chloro-9-[3-(2-furanyl)-2-propenyloxy]-2,3,4,5- tetrahydro-3-methyl-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2- thienylmethoxy)-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(3- thienylmethoxy)-lH-3-benzazepine; 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H- pyrazol-1-yl)ethoxy]-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4- triazol-1-ylmethoxy)-lH-3-benzazepine; 


 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4- ρyridinylmethoxy)-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H-1,2,4- triazol-1-yl)ethoxy]-lH-3-benzazepine; 6-chloro-9-[ (4-chloro-lH-pyrazol-l-ylmethoxy)- methyl]
-2,3, ,5-tetrahydro-3-methyl-lH-3-benzazepine;
6-chloro-9-[(4-chloro-lH-pyrazol-l-ylmethoxy)- carbonyl]-2,3,4,5-tetrahydro-3-methyl-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(lH-pyrrol-1- yl)-lH-3-benzazepine;
6-chloro-9-(2,5-dimethyl-lH-pyrrol-l-yl)-2,3,4,5- tetrahydro-3-methyl-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(lH-pyrrol-1- ylmethyl)-lH-3-benzazepine; 6-chloro-9-[3-(4-chloro-lH-pyrazol-l-yl)propyl]- 2,3, ,5-tetrahydro-3-methyl-lH-3-benzazepine; or
6-chloro-9-[5-(4-chloro-lH-pyrazol-l-yl)pentyl]- 2,3,4,5-tetrahydro-3-methyl-lH-3-benzazepine.
11. A method of antagonizing α-adrenergic receptors in mammals which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.
12. A method of claim 11 wherein the compound is
6-chloro-9-(3-furanylmethoxy)2,3,4,5-tetrahydro-3-methyl- lH-3-benzazepine.
13. A method of claim 11 wherein the compound is: 6-chloro-9-(4-chloro-lH-pyrazol-l-ylmethoxy)- 2,3,4,5-tetrahydro-3-methyl-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(lH-pyrazol- 1-ylmethoxy)-lH-3-benzazepine;
6-chloro-9-(2-furanylmethoxy)-2,3,4,5-tetrahydro-3- methyl-lH-3-benzazepine;
6-chloro-9- [3-(2-furanyl)-2-propenyloxy]-2,3,4,5- tetrahydro-3-methyl-lH-3-benzazepine; 



 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(2- . thienylmethoxy)-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(3- thienylmethoxy)-lH-3-benzazepine; 6-chloro-2,3,4,5-tetrahydro-3-methyl-9-[2-(1H- pyrazol-1-yl)ethoxy]-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(1H-1,2,4- triazol-l-ylmethoxy)-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(4- pyridinylmethoxy)-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9- [2-(1H-1,2,4- triazol-1-yl)ethoxy]-lH-3-benzazepine;
6-chloro-9-[ (4-chloro-lH-pyrazol-l-ylmethoxy)- methyl]-2,3,4,5-tetrahydro-3-methyl-lH-3-benzazepine; 6-chloro-9-[ (4-chloro-lH-pyrazol-l-ylmethoxy)- carbonyl]
-2,3, ,5-tetrahydro-3-methyl-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(lH-pyrrol-1- yl)-lH-3-benzazepine;
6-chloro-9-(2,5-dimethyl-lH-pyrrol-l-yl)-2,3,4,5- tetrahydro-3-methyl-lH-3-benzazepine;
6-chloro-2,3,4,5-tetrahydro-3-methyl-9-(lH-pyrrol-1- ylmethyl)-lH-3-benzazeρine;
6-chloro-9-[3-(4-chloro-lH-pyrazol-l-yl)propyl]- 2,3,4,5-tetrahydro-3-methyl-lH-3-benzazepine; or 6-chloro-9-[5-(4-chloro-lH-pyrazol-l-yl)pentyl]
- 2,3,4,5-tetrahydro-3-methyl-lH-3-benzazepine.
14. A method of treating hypertension in mammals which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.
15. A method of treating congestive heart failure in mammals which comprises administering to a subject in need thereof an effective amount of a compound of claim 1.
16. A method of treating peripheral vascular disease in mammals which comprises administering to a 


subject in need thereof an effective amount of a compound of claim 1.
17. A method of treating benign prostatic hypertrophy in mammals which comprises administering to a subject in need thereof an effective amount of a compound of claim 1. 

</CLAIMS>
</TEXT>
</DOC>
